The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors.
Paola V Plazas; Jessica Savino; Sebastian Kracun; María E Gomez-Casati; Eleonora Katz; Christopher G Parsons; Neil S Millar; Ana B Elgoyhen (Profiled Author: Ana Elgoyhen)
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina. email@example.com
European journal of pharmacology 2007;566(1-3):11-9.
In this study we report the effects of neramexane, a novel amino-alkyl-cyclohexane derivative that is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, on recombinant rat alpha9alpha10 nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. We compared its effects with those of memantine, a well-studied pore blocker of NMDA receptors, currently used in therapeutics for the treatment of Alzheimer's disease. Our results indicate that both compounds block acetylcholine-evoked responses at micromolar concentrations with a rank order of potency of neramexane>memantine, P<0.05. Block by neramexane of acetylcholine responses was not overcome at high concentrations of the agonist, indicative of a non-competitive inhibition. The lack of interaction of neramexane with the ligand binding domain was confirmed by radioligand binding experiments in transfected tsA201 cells. Moreover, block did not involve an increase in desensitization kinetics, it was independent of the resting potential of the membrane at low concentrations of neramexane and slightly voltage-dependent at concentrations higher than 1 microM. Finally, clinically-relevant concentrations of neramexane blocked native alpha9alpha10-containing nicotinic acetylcholine receptors of rat inner hair cells, thus demonstrating a possible in vivo relevance in potentially unexplored therapeutic areas.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
J Michael McIntosh; Paola V Plazas; Maren Watkins; María E Gomez-Casati; Baldomero M Olivera; A Belén ElgoyhenThe Journal of biological chemistry 2005;280(34):30107-12.
Jimena A Ballestero; Paola V Plazas; Sebastian Kracun; María E Gómez-Casati; Julián Taranda; Carla V Rothlin; Eleonora Katz; Neil S Millar; A Belén ElgoyhenMolecular pharmacology 2005;68(3):822-9.
Murat Oz; Shelley N Jackson; Amina S Woods; Marisela Morales; Li ZhangThe Journal of pharmacology and experimental therapeutics 2005;313(3):1272-80.
Appears in this Publication
Author of this Publication